TAC‐tics for Leveraging Proximity Biology in Drug Discovery
Chemically induced proximity (CIP) refers to co‐opting naturally occurring biological pathways using synthetic molecules to recruit neosubstrates that are not normally encountered or to enhance the affinity of naturally occurring interactions. Leveraging proximity biology through CIPs has become a r...
Gespeichert in:
Veröffentlicht in: | Chembiochem : a European journal of chemical biology 2024-02, Vol.25 (4), p.e202300712-n/a |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Chemically induced proximity (CIP) refers to co‐opting naturally occurring biological pathways using synthetic molecules to recruit neosubstrates that are not normally encountered or to enhance the affinity of naturally occurring interactions. Leveraging proximity biology through CIPs has become a rapidly evolving field and has garnered considerable interest in basic research and drug discovery. PROteolysis TArgeting Chimera (PROTAC) is a well‐established CIP modality that induces the proximity between a target protein and an E3 ubiquitin ligase, causing target protein degradation via the ubiquitin‐proteasome system. Inspired by PROTACs, several other induced proximity modalities have emerged to modulate both proteins and RNA over recent years. In this review, we summarize the critical advances and opportunities in the field, focusing on protein degraders, RNA degraders and non‐degrader modalities such as post‐translational modification (PTM) and protein‐protein interaction (PPI) modulators. We envision that these emerging proximity‐based drug modalities will be valuable resources for both biological research and therapeutic discovery in the future.
Chemically induced proximity refers to co‐opting naturally occurring biological pathways using synthetic molecules. These proximity‐inducing modalities are rapidly evolving to offer tremendous opportunities for drug development. This review summarizes the recent advances in the field, focusing on degraders and non‐degrader modalities. |
---|---|
ISSN: | 1439-4227 1439-7633 |
DOI: | 10.1002/cbic.202300712 |